New York, USA, June 26, 2024 (GLOBE NEWSWIRE) -- GLP-1 Agonists Market to Grow Rapidly by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca
The GLP-1 agonists market is poised for exponential growth fueled by advancements in drug delivery systems and expanding indications. Increased awareness of their efficacy in managing diabetes and obesity will drive demand, while research into novel formulations enhances patient adherence. With a growing emphasis on personalized medicine, these therapies are set to revolutionize metabolic disorder treatment paradigms.
DelveInsight’s GLP-1 Agonists Market Insights report includes a comprehensive understanding of current treatment practices, emerging GLP-1 agonists, market share of individual therapies, and current and forecasted GLP-1 agonists market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the GLP-1 Agonists Market Report
- As per DelveInsight’s analysis, the GLP-1 agonists market is anticipated to grow at a significant CAGR by 2034.
- Leading GLP-1 agonist companies such as Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca, and others are developing novel GLP-1 agonists that can be available in the GLP-1 agonists market in the coming years.
- Some of the key GLP-1 agonists include Saxenda, Enobosarm, VK2735, TERN-601, and ECC5004, among others.
- In March 2024, Viking Therapeutics, Inc. revealed encouraging outcomes from their Phase I trial involving multiple doses of an oral tablet version of VK2735. This compound acts as a dual stimulator of both the GLP-1 and GIP receptors, aiming to address metabolic issues like obesity.
- In March 2024, Arecor Therapeutics pl, in partnership with TRx Biosciences Limited, revealed a joint effort to research and develop a formulation for an oral product that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist.
- In November 2023, Terns Pharmaceuticals, Inc. declared the commencement of dosing for the initial participant in the Phase 1 clinical trial of TERN-601, the company's oral small-molecule compound targeting the glucagon-like peptide-1 receptor (GLP-1R), aimed at addressing obesity.
- In November 2023, AstraZeneca and Eccogene made an exclusive deal for ECC5004, a promising oral medication taken once daily that acts as a glucagon-like peptide 1 receptor agonist (GLP-1RA). It's being investigated for its potential in treating obesity, type-2 diabetes, and various other cardiometabolic issues.
Discover which therapies are expected to grab the GLP-1 agonists market share @ GLP-1 Agonists Market Report
GLP-1 Agonists Market Dynamics
The market for GLP-1 agonists has experienced significant growth and evolution in recent years. This growth can be attributed to several key factors, including the increasing prevalence of type 2 diabetes globally, growing awareness about the importance of managing blood sugar levels effectively, and advancements in medical research leading to the development of newer and more effective GLP-1 agonists.
One of the primary drivers of market dynamics in the GLP-1 agonists segment is the constant pursuit of better treatment options with improved efficacy and safety profiles. Pharmaceutical companies are engaged in intense competition to develop and commercialize innovative GLP-1 agonists that offer advantages such as once-weekly dosing, enhanced glycemic control, weight loss benefits, and reduced risk of hypoglycemia. This competition has spurred a wave of research and development activities aimed at bringing novel formulations and delivery mechanisms to the market.
Moreover, the increasing focus on holistic diabetes management and the recognition of GLP-1 agonists as an integral component of comprehensive treatment regimens have contributed to the expanding market demand. Physicians are increasingly prescribing GLP-1 agonists either as monotherapy or in combination with other antidiabetic medications to achieve better glycemic control and address associated comorbidities like obesity and cardiovascular diseases. Additionally, the rise in patient awareness about the importance of proactive diabetes management and the availability of patient support programs have further fueled the demand for GLP-1 agonists.
Another significant aspect shaping the market dynamics of GLP-1 agonists is the evolving regulatory landscape and healthcare reimbursement policies. Regulatory agencies are continuously updating guidelines for diabetes management, including recommendations regarding the use of GLP-1 agonists, which influence prescribing practices and market penetration. Furthermore, favorable reimbursement policies and formulary inclusion decisions by insurance providers and government healthcare agencies play a crucial role in determining patient access to these medications, thereby impacting market uptake and sales.
Overall, the GLP-1 agonists market is characterized by rapid innovation, intense competition, growing demand driven by healthcare trends and patient needs, and evolving regulatory and reimbursement landscapes. These dynamics are likely to continue shaping the market as pharmaceutical companies strive to develop next-generation GLP-1 agonists and stakeholders work to optimize access and utilization of these medications in diabetes management protocols.
GLP-1 Agonists Treatment Market
GLP-1 agonists represent a significant advancement in the management of type 2 diabetes mellitus. Several GLP-1 agonists have received FDA approval for the treatment of type 2 diabetes. Among them, exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide are commonly prescribed medications. Each of these agents has unique characteristics, such as dosing frequency, delivery method, and efficacy profiles, allowing healthcare providers to tailor treatment regimens to individual patient needs. The approval of these medications underscores their safety and efficacy in managing diabetes, offering patients and clinicians a diverse array of options to achieve glycemic control and mitigate cardiovascular risk.
In 2019, the FDA approved Rybelsus (semaglutide) as the first oral GLP-1 treatment for type 2 diabetes. Unlike other GLP-1 drugs, Rybelsus does not require injections. It helps improve blood sugar control by slowing digestion, reducing liver sugar production, and enhancing insulin secretion. Patients now have an alternative to injections for managing their condition
In addition to their established role in diabetes management, ongoing research suggests potential applications of GLP-1 agonists in other metabolic conditions, such as obesity and non-alcoholic fatty liver disease (NAFLD). With their favorable safety profiles and demonstrated efficacy, GLP-1 agonists continue to garner attention as promising therapeutic agents beyond the realm of diabetes. As research advances and our understanding of these medications deepens, their potential to improve outcomes for patients with metabolic disorders remains a compelling area of exploration and development in the field of medicine.
Learn more about the FDA-approved GLP-1 agonists @ GLP-1 Agonists Drugs
Key Emerging GLP-1 Agonistss and Companies
- Saxenda: Novo Nordisk A/S
- Enobosarm: Veru Inc.
- VK2735: Viking Therapeutics, Inc.
- TERN-601: Terns Pharmaceuticals, Inc.
- ECC5004: Eccogene/AstraZeneca
The anticipated launch of these emerging therapies are poised to transform the GLP-1 agonists market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GLP-1 agonists market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about GLP-1 agonists clinical trials, visit @ GLP-1 Agonists Treatment Drugs
GLP-1 Agonists Overview
GLP-1 agonists, a class of medications primarily used in the management of type 2 diabetes, have garnered significant attention due to their multifaceted therapeutic benefits. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone that regulates blood sugar levels by stimulating insulin release and inhibiting glucagon secretion. By enhancing glucose-dependent insulin secretion and promoting satiety, GLP-1 agonists help control blood glucose levels without causing hypoglycemia. Beyond glycemic control, they also demonstrate favorable effects on body weight, as they slow gastric emptying and reduce appetite. Additionally, GLP-1 agonists have been associated with cardiovascular benefits, including reductions in blood pressure and improvements in lipid profiles, making them valuable agents in the comprehensive management of type 2 diabetes and its associated comorbidities.
Furthermore, the administration of GLP-1 agonists has expanded beyond diabetes management, with their potential application in obesity treatment. By targeting appetite control and energy balance mechanisms, these agents offer promise in aiding weight loss efforts in individuals with obesity, particularly when used in conjunction with lifestyle modifications. Their favorable safety profile and potential to mitigate cardiovascular risk factors make them attractive options in addressing the global epidemic of obesity and its related complications. Ongoing research continues to explore the full scope of benefits offered by GLP-1 agonists, positioning them as versatile therapeutics in the realm of metabolic health.
GLP-1 Agonists Epidemiology Segmentation
The GLP-1 agonists report takes into the account of historical, current, and forecasted GLP-1 agonists patient pool. The GLP-1 agonists market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Cases by Indication
- Treatable Cases by Indication
Download the report to understand what epidemiologists are saying about how GLP-1 agonists patient trends in 7MM @ GLP-1 Agonists Epidemiological Insights
| GLP-1 Agonists Report Metrics | Details |
| Study Period | 2020–2034 |
| GLP-1 Agonists Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key GLP-1 Agonists Companies | Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca, and others |
| Key GLP-1 Agonists | Saxenda, Enobosarm, VK2735, TERN-601, and ECC5004, among others |
Scope of the GLP-1 Agonists Market Report
- GLP-1 Agonists Therapeutic Assessment: GLP-1 Agonists current marketed and emerging therapies
- GLP-1 Agonists Market Dynamics: Attribute Analysis of Emerging GLP-1 Agonists Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, GLP-1 Agonists Market Access and Reimbursement
Discover more about GLP-1 agonists drugs in development @ GLP-1 Agonists Clinical Trials
Table of Contents
| 1. | GLP-1 Agonists Market Key Insights |
| 2. | GLP-1 Agonists Market Report Introduction |
| 3. | GLP-1 Agonists Market Overview at a Glance |
| 4. | GLP-1 Agonists Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | GLP-1 Agonists Treatment and Management |
| 7. | GLP-1 Agonists Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | GLP-1 Agonists Marketed Drugs |
| 10. | GLP-1 Agonists Emerging Drugs |
| 11. | Seven Major GLP-1 Agonists Market Analysis |
| 12. | GLP-1 Agonists Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Obesity Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key obesity companies, including 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina Pharma, Clayton Biotech, Click Therapeutics, Corbus Pharma, DiscoveryBiomed Inc, Dong-A ST, Dongkook Pharmaceuticals, Eccogene, Elevian, Eli Lilly and Company, Empros Pharma, Enterin Inc., EraCal Therapeutics AG, ERX Pharmaceuticals, ERX Pharmaceuticals, Eternygen GmbH, Eurofarma, Gannex Pharma, Glaceum, Gmax Biopharm, GPER G-1 Development Group, LLC, Gubra Therapeutics, Hanmi Pharmaceutical, Hanmi Pharmaceuticals, Innovent Biologics, Jenrin Discovery, Jiangsu Hansoh Pharmaceutical, Kallyope, Kintai Therapeutics, Kriya Therapeutics, LG Life Sciences, Lipidio Pharmaceuticals, MakScientific, Nano Precision Medical, NeonMind Biosciences, Novartis, Novo Nordisk, NuSirt Biopharma, Otsuka Pharmaceutical Factory Inc, Pfizer, Raziel Therapeutics, Reata Pharmaceuticals, Regeneron Pharmaceuticals, Reviva Pharmaceuticals, Rivus Pharmaceuticals, Shionogi, SHIONOGI & Co., Ltd., Sigrid Therapeutics, SJT Molecular Research SL, Structure Therapeutics, Sun Pharmaceutical Industries, Techfields Pharma, Terns Pharmaceuticals, Tonix Pharmaceuticals, UGISense AG, Versanis Bio, Viking Therapeutics, YSOPIA Bioscience, Yuhan, Zealand Pharma, among others.
Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen, Novo Nordisk, Prevention Bio, among others.
Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.
Diabetes Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetes companies, including Daewoong Pharmaceutical, Janssen Biotech, Zealand Pharma, BioRestorative Therapies, Elevian, Oramed Pharmaceuticals, ImCyse, Novo Nordisk, Enthera, Precigen, Inc., Japan Tobacco, Avotres, AstraZeneca, Landos Biopharma, Vertex Pharmaceuticals, REMD Biotherapeutics, Inc., Eledon Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, Diamyd Medical, NextCell Pharma, ViaCyte, Op-T LLC, Dompé Farmaceutici S.p.A, ILTOO Pharma, Throne Biotechnologies, Oramed Pharmaceuticals, Janssen Research & Development, LLC, Jaguar Gene Therapy, SQZ Biotechnologies, Genprex, Inc., CRISPR Therapeutics, Biora Therapeutics, Genprex, Inc., among others.
Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, AstraZeneca, Novartis, among others.
Type 2 Diabetes Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key type 2 diabetes companies, including Sanofi, Eli Lilly and Company, Novartis, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
